611 / 881
German Cancer Consortium (DKTK)
DOSE CONSTRAINTS
Maximum tolerated doses and optimum fractionation for mediastinal structures is
currently unknown
Toxicity for SBRT delivered to central tumors is not well documented
Serious doubts in the validity of available data, mostly coming from retrospective
series with small sample sizes
Lacking, incomplete or inconsistent reporting on dose specification
Questionable use of EqD2, α/ß-ratios, LQM estimates
Summary of current experiences in dose/ fraction - toxicity coherences after
SBRT to the mediastinal structures that lead to LungTech normal tissue constraints